- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02981628
Inotuzumab ozogamicin v léčbě mladších pacientů s B-lymfoblastickým lymfomem nebo relapsem nebo refrakterní CD22 pozitivní B akutní lymfoblastickou leukémií
Studie fáze 2 inotuzumab ozogamicinu (NSC# 772518) u dětí a mladých dospělých s relapsující nebo refrakterní CD22+ B-akutní lymfoblastickou leukémií (B-ALL)
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
- Lék: Cyclophosphamide
- Postup: Biospecimen Collection
- Lék: Vincristine
- Postup: Lumbar Puncture
- Biologický: Inotuzumab Ozogamicin
- Lék: Asparaginase Erwinia chrysanthemi
- Postup: Bone Marrow Aspiration and Biopsy
- Lék: Calaspargase Pegol
- Lék: Cytarabine
- Postup: Diagnostic Imaging Testing
- Lék: Leucovorin Calcium
- Lék: Methotrexate
- Lék: Pegaspargase
Detailní popis
PRIMARY OBJECTIVE:
I. To determine the morphologic response rate (complete response [CR] + complete response with incomplete hematologic recovery [CRi]) following one cycle of treatment with inotuzumab ozogamicin in children with relapsed or refractory CD22+ B acute lymphoblastic leukemia (B-ALL). (Cohort 1)
SECONDARY OBJECTIVES:
I. To determine the CR/CRi rate following 2 cycles of inotuzumab ozogamicin therapy. (Cohort 1) II. To determine the safety of single agent inotuzumab ozogamicin administered at the adult recommended phase 2 dose (RP2D) to pediatric patients with relapsed or refractory CD22+ B-ALL. (Cohort 1) III. To determine the level of minimal residual disease (MRD) by flow cytometry in responding patients. (Cohorts 1 and 2) IV. To determine the incidence, severity, and outcomes of sinusoidal obstruction syndrome (SOS) of the liver in patients during inotuzumab ozogamicin therapy and following subsequent treatment, including myeloablative hematopoietic stem cell transplantation (HSCT). (Cohorts 1 and 2) V. To estimate the 3-year event-free survival (EFS), 3-year overall survival (OS), and among responders, duration of CR/CRi for pediatric patients with relapsed or refractory B-ALL treated with inotuzumab ozogamicin. (Cohort 1) VI. To describe inotuzumab ozogamicin pharmacokinetics and immunogenicity in pediatric patients in the presence of overt leukemia and in remission. (Cohort 1) VII. To determine the safe and tolerable dose of inotuzumab ozogamicin in combination with the augmented modified Berlin-Frankfurt-Munster (mBFM) consolidation chemotherapy backbone. (Cohort 2)
EXPLORATORY OBJECTIVES:
I. To describe the levels of leukemic blast CD22 surface expression and site density, and to explore the correlation with cytogenetics and clinical outcomes after treatment with inotuzumab ozogamicin. (Cohorts 1 and 2) II. To explore potential mechanisms of resistance to inotuzumab ozogamicin therapy including CD22 splice variants and intracellular signaling pathways. (Cohorts 1 and 2) III. To explore the impact of inotuzumab ozogamicin on humoral immune function and peripheral B cell populations. (Cohorts 1 and 2) IV. To describe the level of MRD by next-generation high-throughput sequencing (HTS) techniques which may detect low level leukemic blast populations that have altered CD22 expression. (Cohorts 1 and 2) V. To prospectively explore candidate SOS biomarkers including the endothelial marker of inflammation Angiopoietin 2 (Ang2) and the hepatic specific complement marker L-ficolin. (Cohorts 1 and 2) VI. To explore the use of prophylactic ursodeoxycholic acid (UDCA) to prevent hepatic damage and SOS during inotuzumab ozogamicin therapy and subsequent HSCT. (Cohorts 1 and 2) VII. To describe the interaction between inotuzumab ozogamicin and chimeric antigen receptor (CAR) T cell therapy before or after treatment with inotuzumab ozogamicin. (Cohorts 1 and 2) VIII. To estimate the CR/CRi rate following one cycle of inotuzumab ozogamicin plus augmented mBFM consolidation chemotherapy (first 42 days) and following 2 cycles within the confines of a pilot study. (Cohort 2)
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients receive inotuzumab ozogamicin intravenously (IV) over 60 minutes on days 1, 8, and 15 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. (COMPLETE)
COHORT II: Patients receive inotuzumab ozogamicin IV over 60 minutes on days 1, and 8. Patients also receive cyclophosphamide IV over 30-60 on day 1; cytarabine IV over 1-30 minutes or subcutaneously (SC) on days 1-4 and 8-11; leucovorin calcium orally (PO) or IV on days 2, 9, 16, 23 and 37 of cycle 1 and days 9 and 37 of cycle 2; pegaspargase or calaspargase pegol IV over 1-2 hours or pegaspargase intramuscularly (IM) on day 15; and vincristine IV on days 15 and 22. Patients receive methotrexate intrathecally (IT) on days 1, 8 and 36 of cycle 1 and day 36 of cycle 2 for CNS 1 patients, days 1, 8, 15, 22 and 36 of cycle 1, and day 36 of cycle 2 for CNS 2 patients. CNS 3 patients receive methotrexate intrathecal triple therapy (ITT) IT on days 1, 8, 15, 22 and 36 of cycle 1 and days 8 and 36 of cycle 2. There are 3 dose levels. If excessive toxicity is observed at dose level 1, the dosing of inotuzumab ozogamicin will be decreased for dose level -1 and 6-mercaptopurine omitted. If excessive toxicity is observed at this dose, then for dose level -2, the dosing of inotuzumab ozogamicin and cyclophosphamide will be decreased. Treatment repeats every 42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration or biopsy, lumbar puncture, and blood sample collection throughout the trial. Patients also undergo imaging on screening and on study.
After completion of study treatment, patients are followed up at 30 days, every 3 months for 1 year, and then yearly for 4 years.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Caguas, Portoriko, 00726
- HIMA San Pablo Oncologic Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- Children's Hospital of Alabama
-
-
Alaska
-
Anchorage, Alaska, Spojené státy, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Spojené státy, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Spojené státy, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, Spojené státy, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Spojené státy, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Spojené státy, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Spojené státy, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Spojené státy, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Spojené státy, 90027
- Children's Hospital Los Angeles
-
Madera, California, Spojené státy, 93636
- Valley Children's Hospital
-
Oakland, California, Spojené státy, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Spojené státy, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Spojené státy, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Spojené státy, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Spojené státy, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Spojené státy, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Spojené státy, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Spojené státy, 94158
- UCSF Medical Center-Mission Bay
-
Torrance, California, Spojené státy, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Spojené státy, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Spojené státy, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Spojené státy, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20010
- Children's National Medical Center
-
-
Florida
-
Fort Myers, Florida, Spojené státy, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Spojené státy, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Spojené státy, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Spojené státy, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Spojené státy, 33155
- Nicklaus Children's Hospital
-
Orlando, Florida, Spojené státy, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Spojené státy, 32803
- AdventHealth Orlando
-
Pensacola, Florida, Spojené státy, 32504
- Nemours Children's Clinic - Pensacola
-
St. Petersburg, Florida, Spojené státy, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Spojené státy, 33606
- Tampa General Hospital
-
Tampa, Florida, Spojené státy, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, Spojené státy, 33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Savannah, Georgia, Spojené státy, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Spojené státy, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Spojené státy, 60611
- Lurie Children's Hospital-Chicago
-
Maywood, Illinois, Spojené státy, 60153
- Loyola University Medical Center
-
Peoria, Illinois, Spojené státy, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Spojené státy, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, Spojené státy, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, Spojené státy, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Spojené státy, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Spojené státy, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Spojené státy, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Spojené státy, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Spojené státy, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Spojené státy, 21215
- Sinai Hospital of Baltimore
-
Bethesda, Maryland, Spojené státy, 20892
- National Institutes of Health Clinical Center
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Spojené státy, 02111
- Tufts Children's Hospital
-
Worcester, Massachusetts, Spojené státy, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- C S Mott Children's Hospital
-
East Lansing, Michigan, Spojené státy, 48823
- Michigan State University
-
Grand Rapids, Michigan, Spojené státy, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Royal Oak, Michigan, Spojené státy, 48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Spojené státy, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, Spojené státy, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, Spojené státy, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Spojené státy, 65212
- University of Missouri Children's Hospital
-
Kansas City, Missouri, Spojené státy, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Spojené státy, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Spojené státy, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Spojené státy, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Spojené státy, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Spojené státy, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Reno, Nevada, Spojené státy, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Spojené státy, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Spojené státy, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Spojené státy, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Spojené státy, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, Spojené státy, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Spojené státy, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Spojené státy, 07503
- Saint Joseph's Regional Medical Center
-
-
New York
-
Albany, New York, Spojené státy, 12208
- Albany Medical Center
-
Brooklyn, New York, Spojené státy, 11219
- Maimonides Medical Center
-
Buffalo, New York, Spojené státy, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Spojené státy, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Spojené státy, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Spojené státy, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Spojené státy, 10029
- Mount Sinai Hospital
-
New York, New York, Spojené státy, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Spojené státy, 14642
- University of Rochester
-
Stony Brook, New York, Spojené státy, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Spojené státy, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Spojené státy, 10467
- Montefiore Medical Center - Moses Campus
-
Valhalla, New York, Spojené státy, 10595
- New York Medical College
-
-
North Carolina
-
Asheville, North Carolina, Spojené státy, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, Spojené státy, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham, North Carolina, Spojené státy, 27710
- Duke University Medical Center
-
Greenville, North Carolina, Spojené státy, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Spojené státy, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Spojené státy, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Spojené státy, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Spojené státy, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Spojené státy, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Spojené státy, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Spojené státy, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97239
- Oregon Health and Science University
-
Portland, Oregon, Spojené státy, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Spojené státy, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Spojené státy, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Spojené státy, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Spojené státy, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Spojené státy, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Spojené státy, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Spojené státy, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Spojené státy, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, Spojené státy, 37403
- T C Thompson Children's Hospital
-
Knoxville, Tennessee, Spojené státy, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Spojené státy, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Spojené státy, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Spojené státy, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Spojené státy, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Spojené státy, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Spojené státy, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Spojené státy, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Spojené státy, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Spojené státy, 76104
- Cook Children's Medical Center
-
Houston, Texas, Spojené státy, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Spojené státy, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Spojené státy, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Spojené státy, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Spojené státy, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Spojené státy, 78229
- Methodist Children's Hospital of South Texas
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington, Vermont, Spojené státy, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, Spojené státy, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Spojené státy, 23507
- Children's Hospital of The King's Daughters
-
-
Washington
-
Seattle, Washington, Spojené státy, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Spojené státy, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
-
West Virginia
-
Morgantown, West Virginia, Spojené státy, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Marshfield, Wisconsin, Spojené státy, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Children's Hospital of Wisconsin
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Patients must be >= 1 year and < 22 years of age at the time of enrollment
-
Patients must have B-ALL, or previously diagnosed B lymphoblastic lymphoma (B-LL), with >= 5% (M2 or M3) bone marrow blasts with or without extramedullary disease
- NOTE: Relapsed patients previously diagnosed with B-lymphoblastic lymphoma (B-LL) are eligible if they have an M2 or M3 marrow at the time of enrollment on this study
-
Patients with ALL or B-LL who have M2 morphology must have local confirmatory testing showing >= 5% blasts by flow cytometry, fluorescence in situ hybridization (FISH) testing or other molecular method
-
Leukemic blasts must demonstrate surface expression of CD22 at the time of relapse by local/institutional flow cytometry of a bone marrow aspirate sample; (assessment of CD22 using a bright fluorophore such as phycoerythrin [PE] is strongly recommended)
- In the case of an inadequate aspirate sample (dry tap) or if bone marrow aspirate is unable to be performed due to patient clinical status, flow cytometry of peripheral blood specimen may be substituted if the patient has at least 1,000/uL circulating blasts; alternatively, CD22 expression may be documented by immunohistochemistry of a bone marrow biopsy specimen
-
Patients with one of the following:
- Second or greater relapse;
- Primary refractory disease with at least 2 prior induction attempts;
- First relapse refractory to at least one prior re-induction attempt
- Any relapse after HSCT (Cohort 1 ONLY)
Patients with Down syndrome are eligible ONLY for Cohort 1 with:
-
Any of above disease status, OR
-
First relapse with no prior re-induction attempt NOTE: Patients with Down syndrome or prior HSCT are NOT eligible for Cohort 2 combination therapy
- Patients with Philadelphia chromosome (Ph)+ ALL must have had two prior therapy attempts including two different tyrosine kinase inhibitors (TKIs)
- Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy, defined as resolution of all such toxicities to =< grade 2 or lower per the inclusion/exclusion criteria prior to entering this study. Apply to Cohort 2:
-
Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive. For agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator prior to enrollment.
-
A waiting period prior to enrollment is not required for patients receiving standard cytotoxic maintenance chemotherapy (i.e., corticosteroid, vincristine, 6MP, and/or methotrexate).
-
A waiting period is not required for patients receiving a single dose of intrathecal methotrexate, hydrocortisone, and/or cytarabine within 7 days prior to enrollment
-
>= 14 days must have elapsed after the completion of other cytotoxic therapy, with the exception of hydroxyurea, for patients not receiving standard maintenance therapy. For patients who previously received calaspargase pegol, >= 21 days must have elapsed after the last dose. Additionally, patients must have fully recovered from all acute toxic effects of prior therapy.
- Note: Cytoreduction with hydroxyurea must be discontinued >= 24 hours prior to the start of protocol therapy.
-
-
Anti-cancer agents not known to be myelosuppressive (e.g., not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent. For agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment.
-
Anti-cancer agents that are antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1. There is an exception for blinatumomab infusions, for which patients must have been off for at least 3 days and all drug related toxicity must have resolved to grade 2 or lower as outlined in the inclusion/exclusion criteria.
-
Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid. A waiting period prior to enrollment is not required for patients receiving corticosteroid for leukemia therapy/cytoreduction.
-
Radiotherapy: >= 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); >= 3 months must have elapsed if prior cranial or craniospinal XRT was received, if >= 50% of the pelvis was irradiated, or if total body irradiation (TBI) was received; >= 6 weeks must have elapsed if other substantial bone marrow irradiation was given.
-
Stem cell transplant or rescue without TBI: For Cohort 1, at least 90 days must have elapsed since stem cell transplant and at least 30 days from donor lymphocyte infusion. Patient must have had no more than one previous HSCT and currently have no evidence of active graft vs. host disease (GVHD). For Cohort 2, no prior HSCT is allowed.
-
Chimeric antigen receptor (CAR) T cell therapy: At least 30 days must have elapsed from the last CAR-T cell infusion
- Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or
- A serum creatinine based on age/sex as follows:
-
1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
-
2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
-
6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
-
10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
-
13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
-
>= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
- Direct bilirubin =< 1.5 x upper limit of normal (ULN) for age, and
- Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5 x ULN for age; for the purpose of this study, the ULN for ALT will be 45 U/L
Exclusion Criteria:
-
Patients with any prior history of SOS irrespective of severity
-
Patients with isolated central nervous system (CNS), testicular, or any other extramedullary site of relapse
-
Patients who have been previously treated with inotuzumab ozogamicin
-
Patients who have previously received HSCT (Cohort 2 only)
-
Patients with Down syndrome (Cohort 2 only)
-
History of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the study
- Note: Patients with history of allergy to pegaspargase/calaspargase pegol are eligible for enrollment on Cohort 2 if Erwinia formulation of asparaginase can be obtained
-
Patients with active optic nerve and/or retinal involvement are not eligible; patients who are presenting with visual disturbances should have an ophthalmologic exam and, if indicated, a magnetic resonance imaging (MRI) to assess optic nerve or retinal involvement
-
Patients who are currently receiving another investigational drug
-
Patients who are currently receiving or plan to receive other anti-cancer agents (except hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy, and intrathecal chemotherapy)
-
Anti-GVHD or agents to prevent organ rejection post-transplant; patients who are receiving cyclosporine, tacrolimus, or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial; at least 3 half-lives must have elapsed after the last dose of GVHD or anti-rejection medications
-
Patients who are currently receiving or plan to receive corticosteroids except as described below
- Systemic corticosteroids may be administered for cytoreduction up to 24 hours prior to the start of protocol therapy, (Cohort 1 only) for all patients, corticosteroids may be administered as a premedication for inotuzumab ozogamicin and as treatment for allergic reactions or for physiologic replacement/stress dosing of hydrocortisone for documented adrenal insufficiency; corticosteroids are not allowed for other indications
-
Patients with known human immunodeficiency virus (HIV), hepatitis B or C infections; testing to prove negative status is not required for enrollment unless it is deemed necessary for usual medical care of the patient
-
Patients who have an active uncontrolled infection defined as:
- Positive bacterial blood culture within 48 hours of study enrollment;
- Fever above 38.2 degree Celsius (C) within 48 hours of study enrollment with clinical signs of infection; fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability
- A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection
- Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection as long as cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved; for patients with clostridium (C.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline
- Active viral or protozoal infection requiring IV treatment
-
Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Schwachman (Schwachman-Diamond-Blackfan) syndrome or any other known bone marrow failure syndrome
-
There have been no human studies of inotuzumab ozogamicin in pregnant women and no reports of exposure in utero; based on nonclinical safety studies, inotuzumab ozogamicin has the potential to impair human male and female fertility and to adversely affect human embryo fetal development; women of childbearing potential should be advised to avoid becoming pregnant while receiving inotuzumab ozogamicin; there is no information regarding the presence of inotuzumab ozogamicin in human milk, the effects on the breast-fed infant, or the effects on milk production; because of the potential for adverse reactions in breast-fed infants, women should not breast-feed during treatment with inotuzumab ozogamicin and for at least 2 months after the final dose
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days prior to enrollment
- Female patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of their study participation and for 8 months after the last dose of inotuzumab ozogamicin
- Men with female partners of childbearing potential should use effective contraception during treatment with inotuzumab ozogamicin and for at least 5 months after the last dose of inotuzumab ozogamicin
- Lactating females are not eligible unless they agree not to breastfeed their infants
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Cohort I (inotuzumab ozogamicin)
Patients receive inotuzumab ozogamicin IV over 60 minutes on days 1, 8, and 15 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. (COMPLETE) |
Given IV
Ostatní jména:
|
|
Experimentální: Cohort II (inotuzumab ozogamicin, mBFM chemotherapy)
See Detailed Description |
Given IV
Ostatní jména:
Undergo blood sample collection
Ostatní jména:
Given IV
Ostatní jména:
Undergo lumbar puncture
Ostatní jména:
Given IV
Ostatní jména:
Given Asparaginase Erwinia chrysanthemi
Ostatní jména:
Undergo a bone marrow aspiration and biopsy Given IV
Ostatní jména:
Given IV or SC
Ostatní jména:
Undergo imaging
Ostatní jména:
Given PO or IV
Ostatní jména:
Given IT
Ostatní jména:
Given IV or IM
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Morphologic response (complete response [CR]+ incomplete hematologic recovery [CRi]) following one cycle of treatment with inotuzumab ozogamicin (Cohort 1)
Časové okno: Up to 28 days
|
The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated. |
Up to 28 days
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Morphologic response (CR + CRi) following 2 cycles of inotuzumab ozogamicin therapy (Cohort1)
Časové okno: Up to 56 days
|
The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. |
Up to 56 days
|
|
Incidence of dose-limiting toxicities at recommended phase II dose (RP2D) (Cohort 1)
Časové okno: During Cycle 1, up to 28 days
|
Evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Toxicity tables will be constructed to summarize the observed incidence by type of toxicity and grade. For a given reporting period, a patient will be counted only once for a given toxicity for the worst grade of that toxicity reported for that patient. |
During Cycle 1, up to 28 days
|
|
Level of minimal residual disease (MRD) assessed in bone marrow by flow cytometry (Cohort 1 and 2)
Časové okno: Up to 2 cycles
|
MRD negativity rates (< 0.01% detectable leukemia cells) will be estimated. |
Up to 2 cycles
|
|
Incidence of adverse events of sinusoidal obstruction syndrome (SOS) of liver (Cohort 1 and 2)
Časové okno: Up to 1 year from last dose of Inotuzumab ozogamicin
|
Evaluated according to NCI CTCAE version 5.0. The incidence of SOS of the liver in patients during inotuzumab ozogamicin therapy and following subsequent treatment including myeloablative hematopoietic cell transplantation (HSCT) will be described. |
Up to 1 year from last dose of Inotuzumab ozogamicin
|
|
Event free survival (EFS) (Cohort 1)
Časové okno: From study entry to first event (induction failure, induction death, relapse, second malignancy, remission death), or date of last follow-up for event free subjects, assessed up to 3 years
|
The EFS rate will be estimated using Kaplan Meier approach. |
From study entry to first event (induction failure, induction death, relapse, second malignancy, remission death), or date of last follow-up for event free subjects, assessed up to 3 years
|
|
Overall survival (OS) (Cohort 1)
Časové okno: From the time from study entry to death or date of last follow-up, assessed up to 3 years
|
The OS rate will be estimated using Kaplan Meier approach. |
From the time from study entry to death or date of last follow-up, assessed up to 3 years
|
|
Duration of CR, CRi (Cohort 1)
Časové okno: Up to 3 years
|
Among responding patients, three-year complete continuous response will also be estimated using duration of CR/CRi for the overall responding group and stratified by whether or not the patients proceed to HSCT. |
Up to 3 years
|
|
Pharmacokinetic (PK) parameters, i.e., inotuzumab ozogamicin trough levels (Cohort 1)
Časové okno: Cycles 1 and 2 (each cycle is 28 days)
|
Inotuzumab ozogamicin trough levels (ng/mL) will be determined in serum by validated, high sensitivity liquid chromatography-mass spectrometry (LCMS) assays. Descriptive summary statistics will be provided for the trough levels at scheduled visits for Cycles 1 and 2. |
Cycles 1 and 2 (each cycle is 28 days)
|
|
Immunogenicity (Cohort 1)
Časové okno: Cycles 1 and 2
|
Enhanced chemiluminescence (ECL) and cell-based assays will be used to detect anti-drug antibodies and neutralizing antibodies to inotuzumab ozogamicin in serum. Inotuzumab ozogamicin trough levels will be compared between patients with and without antibodies. |
Cycles 1 and 2
|
|
Incidence of dose-limiting toxicities at the selected dose level of inotuzumab ozogamicin in combination with the augmented modified Berlin-Frankfurt-Munster (mBFM) consolidation chemotherapy (Cohort 2)
Časové okno: Up to cycle 1 (each cycle is 42 days)
|
Evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Toxicity tables will be constructed to summarize the observed incidence by type of toxicity and grade. For a given reporting period, a patient will be counted only once for a given toxicity for the worst grade of that toxicity reported for that patient. |
Up to cycle 1 (each cycle is 42 days)
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Changes in CD22 surface expression (Cohorts 1 and 2)
Časové okno: Baseline, post Cycle 1, and at time of relapse
|
Exploratory analysis of CD22 will focus primarily on the comparison of paired pre-treatment and post-treatment samples at the following times, 1) End of cycle 1 and 2) at relapse to evaluate for changes in CD22 expression pre and post-inotuzumab ozogamicin. Specifically, samples will be evaluated for change in CD22 expression that occurs over time to study the role of CD22 expression as it relates to resistance to therapy or mechanism for relapse. Correlation between changes in CD22 expression and patient's clinical response to inotuzumab ozogamicin as well as cytogenetic/molecular features will be described, in particular to explore the association of CD22-negative subpopulations in patients with KMT2A-rearranged acute lymphoblastic leukemia (ALL). |
Baseline, post Cycle 1, and at time of relapse
|
|
Change in CD22 site density (Cohorts 1 and 2)
Časové okno: Baseline, post Cycle 1, and at time of relapse
|
Exploratory analysis of CD22 will focus primarily on the comparison of paired pre-treatment and post-treatment samples at the following times, 1) End of cycle 1 and 2) at relapse to evaluate for changes in CD22 site density pre and post-inotuzumab ozogamicin. Samples will be evaluated for any change in CD22 site density that occurs over time and to evaluate for the emergence of a CD22 "dim" or "negative" population to study the role of CD22 site density as it relates to resistance to therapy or mechanism for relapse. Correlation between changes in CD22 site density and patient's clinical response to inotuzumab ozogamicin as well as cytogenetic/molecular features will be described, in particular to explore the association of CD22-negative subpopulations in patients with KMT2A-rearranged acute lymphoblastic leukemia (ALL). |
Baseline, post Cycle 1, and at time of relapse
|
|
Leukemic blast CD22 splice variants (Cohorts 1 and 2)
Časové okno: Baseline, post-Cycle 1, and at time of relapse
|
Will be analyzed by ribonucleic acid-sequencing (RNA-Seq). The MAJIQ and VOILA software will be used to identify splicing variations in CD22 from RNA Seq and to quantitate the percent spliced in (PSI) of the alternative exons. CD22 protein levels will be determined by immunoblotting of whole cell protein lysates using several anti-CD22 antibodies recognizing either extracellular or intracellular domains. Both protein sizes and preservation of individual epitopes will be assessed and correlated with alterations in exon inclusion. |
Baseline, post-Cycle 1, and at time of relapse
|
|
Intracellular signaling pathways in leukemic blasts treated with inotuzumab ozogamicin (Cohorts 1 and 2)
Časové okno: Baseline up to 5 years
|
Peripheral blood samples will be evaluated by comprehensive protein profiling using CyTOF panels for the two major areas of analyses, surface immunophenotyping to assess the developmental stage of both normal and abnormal B cells and measure their responses to inotuzumab ozogamicin , as well as intracellular epitopes to assess the cellular consequences of treatment with inotuzumab ozogamicin. Exploratory analysis will be performed using Cytobank software tools (viSNE, SPADE and CITRUS) for subpopulations clustering, dimensionality reduction and hierarchical organization. |
Baseline up to 5 years
|
|
Changes in peripheral blood absolute B cell numbers and maturation of developing B cell populations with inotuzumab ozogamicin therapy (Cohorts 1 and 2)
Časové okno: Baseline up to 5 years
|
Descriptive statistics will be used to characterize patterns of B-cell development including selective loss of subsets. Changes in B cell number and subsets will be described, and exploratory analysis will be conducted to assess their correlation with clinical features including immunoglobulin levels, occurrence of infections, and need for intravenous immunoglobulin (IVIG) replacement during inotuzumab ozogamicin therapy. |
Baseline up to 5 years
|
|
Level of MRD by next-generation high-throughput sequencing (HTS) techniques (Cohorts 1 and 2)
Časové okno: Up to 2 cycles
|
Compared to MRD measured by flow cytometry. MRD levels at each bone marrow evaluation time point will be measured by standard flow cytometry (MRD-negative defined as < 0.01% or 1 leukemic cell in 10-4 nucleated cells). At the end of cycles 1 and 2, MRD will also be assessed by HTS. The correlation between the measurements with each technique will be described and the sensitivity of flow-based MRD methodology in the setting of CD22-targeted therapy will be explored. |
Up to 2 cycles
|
|
Serum levels of candidate SOS biomarkers Ang2 and L ficolin (Cohorts 1 and 2)
Časové okno: Up to 12 months from last dose of inotuzumab ozogamicin
|
Correlated with clinical development of SOS. Descriptive statistics will be used to characterize clinical features of patients experiencing SOS. L-ficolin and Ang2 absolute levels and change in level over time with inotuzumab ozogamicin exposure will be evaluated and correlated with development of SOS. Biomarker levels will be compared using simple comparative statistics between subgroups. |
Up to 12 months from last dose of inotuzumab ozogamicin
|
|
Incidence of SOS in patients who receive prophylaxis with ursodeoxycholic acid (UDCA) during inotuzumab ozogamicin therapy (Cohorts 1 and 2)
Časové okno: Up to 12 months from last dose of inotuzumab ozogamicin
|
Descriptive statistics will be used to characterize clinical features of patients experiencing SOS, potential clinical risk factors, and the impact of ursodeoxycholic acid prophylaxis. |
Up to 12 months from last dose of inotuzumab ozogamicin
|
|
Interaction between CAR- T therapy and inotuzumab ozogamicin (Cohorts 1 and 2)
Časové okno: Up to 5 years
|
Will be evaluated by incidence of hematologic DLT in patients with CAR-T therapy prior to inotuzumab ozogamicin, incidence of post-inotuzumab ozogamicin CAR-T therapy, time to CAR-T therapy after inotuzumab ozogamicin, and B-cell recovery prior to CAR-T therapy after inotuzumab ozogamicin. Will be summarized using descriptive statistics. |
Up to 5 years
|
|
Morphologic response (CR/CRi) (Cohort 2)
Časové okno: Up to 2 cycles (each cycle is 42 days)
|
Will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. Analysis will be mostly descriptive. |
Up to 2 cycles (each cycle is 42 days)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Maureen M O'Brien, Children's Oncology Group
Publikace a užitečné odkazy
Obecné publikace
- O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, Xu X, Yi JS, Harris AC, Brown PA, Borowitz MJ, Militano O, Kairalla J, Devidas M, Raetz EA, Gore L, Loh ML. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022 Mar 20;40(9):956-967. doi: 10.1200/JCO.21.01693. Epub 2022 Jan 10.
- Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704.
- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhadovaný)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary
- Onemocnění imunitního systému
- Infekce
- Virová onemocnění
- Novotvary podle histologického typu
- Hematologická onemocnění
- DNA virové infekce
- Lymfatická onemocnění
- Lymfoproliferativní poruchy
- Imunoproliferativní poruchy
- Lymfom, Non-Hodgkin
- Lymfom, B-buňka
- Lymfom
- Leukémie, lymfoidní
- Leukémie
- Infekce virem Epstein-Barrové
- Herpesviridae infekce
- Nádorové virové infekce
- Lymfoblastická leukémie-lymfom prekurzorových buněk
- Hemická a lymfatická onemocnění
- Burkittův lymfom
- Prekurzorová B-buněčná lymfoblastická leukémie-lymfom
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Organické chemikálie
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Heterocyklické sloučeniny, 2-prsten
- Heterocyklické sloučeniny, fúzované kroužek
- Vyšetřovací techniky
- Terapeutika
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Vpichy
- Chirurgické postupy, operativní
- Cytologické techniky
- Nukleové kyseliny, nukleotidy a nukleosidy
- Cytodiagnosis
- Uhlovodíky
- Uhlohydráty
- Fyzické jevy
- Alkaloidy
- Glykosidy
- Hydrolázy
- Enzymy
- Enzymy a koenzymy
- Indoly
- Protilátky, monoklonální, humanizované
- Protilátky, monoklonální
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Cytidin
- Pyrimidinové nukleosidy
- Pyrimidiny
- Diagnostické techniky, chirurgické
- Fosforamidové hořčice
- Sloučeniny hořčice dusíku
- Hořčičné sloučeniny
- Uhlovodíky, halogenované
- Fosforamidy
- Organofosforové sloučeniny
- Nukleosidy
- Formyltetrahydrofoláty
- Tetrahydrofoláty
- Kyselina listová
- Pteriny
- Pteridiny
- Amidohydrolázy
- Vinca alkaloidy
- Alkaloidy tryptaminu sezologaninu
- Indolské alkaloidy
- Indolizidiny
- Indoliziny
- Arabinonukleosidy
- Aminopterin
- Aminoglykosidy
- Koenzymy
- Elektromagnetické jevy
- Magnetické jevy
- Diagnostické techniky, neurologické
- Elektromagnetické záření
- Záření
- Záření, ionizující
- Kalichemiciny
- Inotuzumab ozogamicin
- Methotrexát
- Cyklofosfamid
- Cytarabin
- Leukovorin
- Vinkristine
- Asparagináza
- Biopsie
- Manipulace se vzorkem
- Spinální punkci
- Rentgenové paprsky
- Calaspargase Pegol
- Merphos
- pegaspargase
- asparagináza erwinia chrysanthemi rekombinantní
Další identifikační čísla studie
- AALL1621
- U10CA180886 (Grant/smlouva NIH USA)
- AALL1621 (Jiný identifikátor: CTEP)
- NCI-2016-01494 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- AALL1621 (Jiný identifikátor: Children's Oncology Group)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .